Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study - PubMed
5 hours ago
- #osteoporosis
- #romosozumab
- #mortality
- Romosozumab showed significantly lower all-cause mortality compared to teriparatide in osteoporosis patients (HR 0.68, 95% CI 0.49-0.94).
- The survival benefit with romosozumab was more pronounced in patients aged ≥60 years (HR 0.65, 95% CI 0.47-0.88).
- No increased cardiovascular mortality risk was observed with romosozumab, even in patients with hypertension or coronary heart disease.
- Subgroup analyses favored romosozumab across conditions like diabetes and chronic kidney disease, though results were not statistically significant.
- Study used real-world data from over 120 healthcare organizations with propensity score matching, involving 2470 patients per treatment group.
- Findings suggest romosozumab as a potentially safer and more effective option for reducing mortality, especially in older adults.